Novedades

• US generics launch and approval for Dr Reddy’s and Lupin
• Five Chinese companies join UN’s MPP for Covid-19 medicines
• South Korean companies to make generic Bridion and COVID-19 drugs
• Revlimid (lenalidomide) generics launch across Europe

Investigación

• New insights into the amount of R & D for new uses of generic drugs
• Pricing and reimbursement of medicines in Canada
• Medicines pricing conditions in Italy and Brazil: comparison of regulations
• Relevance of NTI to the treatment of epilepsy

General

• FDA releases one-year progress report for the Generic Drug Cluster
• Empresas de fabricación de productos farmacéuticos en Brasil
• Empresas farmacéuticas en Argentina
• Empresas farmacéuticas en América Latina y el Caribe

Novedades

• New insulin glargine and potential adalimumab interchangeable biosimilars
• Biosimilar advances for Alvotech-Teva and setback for Biocon Biologics
• Advances for Bio-Thera’s secukinumab and mepolizumab copy biologicals
• FDA and EMA file acceptance of Biogen’s tocilizumab biosimilar

Investigación

• EE.UU. frente a Alemania y Suiza: El mercado estadounidense de biosimilares se queda atrás con precios más altos
• Drug survival of adalimumab biosimilars in psoriasis treatment in Spain
• Pegfilgrastim biosimilars in US supportive oncology
• Investigating cell, tissue and gene therapy products and their regulation

General

• Canada’s Ontario introduces biosimilars switching policy
• Hechos clave en la regulación de la aprobación de biosimilares en Brasil
• La provincia canadiense de Saskatchewan introduce una política de switching de biosimilares
• A Canadian gastro-enterologist’s view on advising on biosimilars

• Latin American Forum
• Fármacos complejos no biológicos
• Enfoque por país

• Directrices
• Políticas y legislación
• Informes

• Congresos
• Artículos patrocinados
• Enlaces patrocinados